Ocuphire Pharma, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Put Feature On Common Stock (Tables)

Put Feature On Common Stock (Tables)

6 Months Ended

Jun. 30, 2012

Put Feature On Common Stock [Abstract]

Summary Of Fair Value Of Anti-Dilution Provision Recorded As Liabilities

Fair Values:		June 30, 2012	December 31, 2011	Transaction Date
December 18, 2007 financing		$ -	$ -	$ 4,401,169
March 20, 2008 financing		-	-	553,569
Total:		$ -	$ -	$ 4,954,738

Summary Of Shares Indexed To The Anti-Dilution Provision

Number of Shares indexed:		June 30, 2012	December 31, 2011	Transaction Date
December 18, 2007 financing		-	-	4,857,159
March 20, 2008 financing		-	-	642,858
Total:		-	-	5,500,017

Schedule Of Anti-Dilution Provision And Significant Valuation Assumptions

December 18, 2007 financing:		June 30, 2012	December 31, 2011	Transaction Date
Trading market prices		$ -	$ -	$ 1.75
Estimated future stock price		-	-	$0.98-$1.75
Estimated future volatility		-	-	143%
Dividend		-	-	-
Estimated future risk-free rate		-	-	3.14%

March 20, 2008 financing:		June 30, 2012	December 31, 2011	Transaction Date
Trading market prices		$ -	$ -	$ 2.14
Estimated future stock price		-	-	$1.36-$2.10
Estimated future volatility		-	-	142%
Dividend		-	-	-
Estimated future risk-free rate		-	-	1.85%

Schedule Of Unrealized Gains Losses On Fair Value Of Anti-Dilution Provision

		Three and Six Months Ended June 30, 2012	Three and Six Months Ended June 30, 2011	Cumulative from March 19, 2001 (Inception) to June 30, 2012
December 18, 2007 financing		$ -	$ -	$ 2,148,418
March 20, 2008 financing		-	-	167,121
Total:		$ -	$ -	$ 2,315,539